These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 39014366)
1. Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring. Tao XY; Li QQ; Zeng Y Mol Cancer; 2024 Jul; 23(1):145. PubMed ID: 39014366 [TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Zhou H; Zhu L; Song J; Wang G; Li P; Li W; Luo P; Sun X; Wu J; Liu Y; Zhu S; Zhang Y Mol Cancer; 2022 Mar; 21(1):86. PubMed ID: 35337361 [TBL] [Abstract][Full Text] [Related]
3. Circulating biomarkers for early detection and clinical management of colorectal cancer. Marcuello M; Vymetalkova V; Neves RPL; Duran-Sanchon S; Vedeld HM; Tham E; van Dalum G; Flügen G; Garcia-Barberan V; Fijneman RJ; Castells A; Vodicka P; Lind GE; Stoecklein NH; Heitzer E; Gironella M Mol Aspects Med; 2019 Oct; 69():107-122. PubMed ID: 31189073 [TBL] [Abstract][Full Text] [Related]
4. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer. Raza A; Khan AQ; Inchakalody VP; Mestiri S; Yoosuf ZSKM; Bedhiafi T; El-Ella DMA; Taib N; Hydrose S; Akbar S; Fernandes Q; Al-Zaidan L; Krishnankutty R; Merhi M; Uddin S; Dermime S J Exp Clin Cancer Res; 2022 Mar; 41(1):99. PubMed ID: 35292091 [TBL] [Abstract][Full Text] [Related]
5. Role of liquid biopsies in colorectal cancer. Wills B; Gorse E; Lee V Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335 [TBL] [Abstract][Full Text] [Related]
6. Clinical utility of circulating tumor DNA for colorectal cancer. Osumi H; Shinozaki E; Yamaguchi K; Zembutsu H Cancer Sci; 2019 Apr; 110(4):1148-1155. PubMed ID: 30742729 [TBL] [Abstract][Full Text] [Related]
7. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review. Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754 [TBL] [Abstract][Full Text] [Related]
8. Clinical Applications of Liquid Biopsy in Colorectal Cancer Screening: Current Challenges and Future Perspectives. Galoș D; Gorzo A; Balacescu O; Sur D Cells; 2022 Nov; 11(21):. PubMed ID: 36359889 [TBL] [Abstract][Full Text] [Related]
9. Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Germano G; Mauri G; Siravegna G; Dive C; Pierce J; Di Nicolantonio F; D'Incalci M; Bardelli A; Siena S; Sartore-Bianchi A Clin Colorectal Cancer; 2018 Mar; 17(1):80-83. PubMed ID: 29195807 [TBL] [Abstract][Full Text] [Related]
10. [Progress of circulating tumor DNA in the clinical management of colorectal cancer]. Jiang ZY; Fu W Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Mar; 27(3):287-294. PubMed ID: 38532593 [TBL] [Abstract][Full Text] [Related]
11. The Significance of Circulating Tumour Cells in the Clinic. Abalde-Cela S; Piairo P; Diéguez L Acta Cytol; 2019; 63(6):466-478. PubMed ID: 30820013 [TBL] [Abstract][Full Text] [Related]
12. Copy Number Variations as Determinants of Colorectal Tumor Progression in Liquid Biopsies. Debattista J; Grech L; Scerri C; Grech G Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675253 [TBL] [Abstract][Full Text] [Related]
13. Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy. Verbanac D; Čeri A; Hlapčić I; Shakibaei M; Brockmueller A; Krušlin B; Ljubičić N; Baršić N; Detel D; Batičić L; Rumora L; Somborac-Bačura A; Štefanović M; Ćelap I; Demirović A; Petlevski R; Petrik J; Grdić Rajković M; Hulina-Tomašković A; Rako I; Saso L; Barišić K Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919272 [TBL] [Abstract][Full Text] [Related]
14. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403 [TBL] [Abstract][Full Text] [Related]
15. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction. Nassar FJ; Msheik ZS; Nasr RR; Temraz SN Clin Epigenetics; 2021 May; 13(1):111. PubMed ID: 34001239 [TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267 [TBL] [Abstract][Full Text] [Related]
18. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay. Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312 [TBL] [Abstract][Full Text] [Related]
19. Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer. Pan X; Zhang X Future Oncol; 2020 Jun; 16(18):1289-1299. PubMed ID: 32379501 [No Abstract] [Full Text] [Related]
20. Perspectives of the Application of Liquid Biopsy in Colorectal Cancer. Ding Y; Li W; Wang K; Xu C; Hao M; Ding L Biomed Res Int; 2020; 2020():6843180. PubMed ID: 32258135 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]